Changes in Beneficial Ownership · 4/A
OKYO Pharma Limited
OKYONASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4/A
ownership.xml
Amendment · This filing reports the amendment as submitted.
Filing details
- Report period
- 2026-07-21
- Original submission
- 2026-07-23
- Issuer
- OKYO Pharma Ltd
- Issuer CIK
- 0001849296
- Trading symbol
- OKYO
Reporting owner 1
- Name
- CERRONE GABRIELE M
- Reporting owner CIK
- 0001139306
- Relationship
- Director · 10% owner
- Address
- 14-15 CONDUIT ST, LONDON, UNITED KINGDOM, X0, W1S 2XJ
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | 2026-07-21 | P · Form 4 | 22,500 | A | 1.45 | 10,873,916 | I | Via Panetta Partners Limited |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- I
- Indirect
Remarks
This Form 4/A amends the Form 4 filed on July 23, 2026 solely to correct the transaction code associated with this open market purchase. No other reported transactions are affected by this amendment.
Signature 1
- Signed
- /s/ Gabriele M. Cerrone
- Date
- 2026-08-07
Company context
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.